fr | en

Atrial fibrillation

Atrial fibrillation, the most common arrhythmia, currently affects more than 10 million people in Europe, with a projection of 14-17 million by 2030.

It is characterized by irregular and rapid heartbeats. Very disabling, its impact on the quality of life of those affected is as great as that of coronary artery disease (myocardial infarction). It is the most common cause of cardioembolic stroke and a risk factor for heart failure and dementia.


Atrial fibrillation manifests itself by an uncontrolled electrical activation and thus an ineffective contraction of the atrium, which promotes the formation of blood clots. The heartbeat becomes rapid and irregular.


Atrial fribrillation can be paroxysmal (multiple episodes usually lasting less than 48 hours and spontaneous termination), persistent (sustained arrhythmia beyond 7 days or needing treatment to stop the arrhythmia) and permanent (lasting over a year). Its appearance is favored by certain pre-existing cardiac disorders (infarction, cardiomyopathy, valve pathology...), hormonal disorders (thyroid), obesity and diabetes. 


Several years ago, Liryc doctors identified the triggers of atrial fibrillation in the pulmonary veins. This discovery led to the development of a non-pharmaceutical treatment of this disease.


This treatment consists of cauterizing the pulmonary veins by a radiofrequency catheter so as to exclude these arrhythmia triggers. This approach has become the treatment of reference: to date, over 300,000 patients are treated annually worldwide.



The cellular mechanisms of venous firing and potential molecular targets are unknown.There are still some areas requiring work, in particular for screening diagnostic and prognostic tools and effective new treatments for this arrhythmia. 

  • To develop better ablation tools for safer, faster and easier procedures.
  • To develop drug therapy, targeting venous cells.
  • To develop biomarkers and new strategies.